FDA Approval of the <em>ReShape</em><sup>®</sup> Procedure Featured on EndocrineWeb

FDA Approval of the ReShape® Procedure Featured on EndocrineWeb

Nonsurgical ReShape Integrated Dual Balloon System Now Approved to Treat Obesity

A new balloon device to treat obesity without the need for invasive surgery was approved by the U.S. Food and Drug Administration (FDA). The ReShape Integrated Dual Balloon System works by occupying space in the stomach, which limits the space for food intake and triggers feelings of fullness.

The ReShape Dual Balloon is indicated for weight reduction in adults with a BMI of 30 to 40 kg/mand 1 or more obesity-related conditions, such as high blood pressure, high cholesterol, and diabetes. It is intended for patients who have failed previous attempts at weight loss through healthy eating and physical activity alone.

To read the full story on EndocrineWeb.com, click here.